10x Genomics (TXG) Stock

Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that it has received approval from the Toronto Stock Exchange (the "TSX") of its notice of intention to make a normal course issuer bid (the "NCIB"). Under the NCIB, Torex is authorized to purchase up to 7,116,777 of its common shares ("Common Shares"), representing approximately 10% of the public float as of November 13, 2024, during the period commencing on November 21, 2024 and ending on November 20, 2025.

Results indicate strong potential to upgrade Inferred Resources to Indicated Resources and expand resources to the north of the deposit (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at EPO. The results to date support Torex's goal of expanding resources to the north of the deposit and upgrading Inferred Resources to Indicated Resources.

Solid financial performance and robust cash generation driven by an all-in sustaining costs margin of 52% (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and nine months ended September 30, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.

Project 87% complete; plant tie-in schedule moves to February; first copper concentrate expected in Q1 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q3 2024 update on the development of its Media Luna Project ("Media Luna") and increases 2024 production guidance with a decision to undertake the tie-ins and upgrades to the processing plant in February 2025. Unless otherwise stated, progress and milestones referenced in this press release are as of September 30, 2024.

10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.

PLEASANTON, Calif. , Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.